Drugs / LY2334737
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01648764 | Sep 2008 → Nov 2012 | cancer, metastatic neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2334737 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01648764 ↗ |
| Modality | Small molecule | — CHEMBL577711 ↗ |
| Route | Oral | “Administered orally” NCT01648764 ↗ |